Strategic Growth Syner-G has recently expanded its capabilities through the launch of 3D Intelligence (3Di) and AI-augmented authoring and knowledge management partnerships, signaling a strong market push into AI-enabled biopharma development services ripe for cross-sell to clients seeking faster IND to NDA timelines.

Integrated platform The firm operates as a Strategic Development & Delivery Partner with integrated scientific, regulatory, technical, and strategic consulting across the development lifecycle, presenting opportunities to upsell end-to-end support to biopharma sponsors undergoing complex regulatory pathways.

Productivity focus Recent leadership hires in Commercial and Operations, plus recognized employer branding as a top place to work, indicate a push to scale client acquisition efforts and deepen account coverage, suggesting readiness for targeted outreach to larger biopharma firms seeking stable partners.

Global reach With 400+ professionals across North America, Europe, and APAC, Syner-G can support multinational development programs, offering conversations around regional regulatory strategy, global filings, and localized clinical operations services to prospective clients with global development needs.

Acquisition momentum The 2023 acquisition of RMC Pharmaceutical Solutions and the 2024 Sequoia Biotech combination indicate an active growth strategy and capability expansion, presenting opportunities to position Syner-G as a consolidator of integrated life-science services for mid-to-large biopharma portfolios.